In vitro activity of BAY 12-8039, a new fluoroquinolone, against mycoplasmas

被引：48
作者：
Bébéar, CM
Renaudin, H
Boudjadja, A
Bébéar, C
机构：
[1] Univ Bordeaux 2, Bacteriol Lab, F-33076 Bordeaux, France
[2] Bayer Pharma, F-92807 Puteaux, France
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1998年 / 42卷 / 03期
关键词：
D O I：
10.1128/AAC.42.3.703
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The in vitro activity of the fluoroquinolone BAY 12-8039 against 66 strains of different mycoplasma species and 30 strains of Ureaplasma urealyticum was compared with those of three other antimicrobial agents. BAY 12-8039 at 0.5 mu g/ml inhibited 100% of all the mycoplasmal and ureaplasmal strains tested. The minimal bactericidal concentrations of BAY 12-8039 increased only two-to eightfold compared to the MICs. Furthermore, they were comparable to those of sparfloxacin and lower than those of doxycycline and clarithromycin.
引用
收藏
页码：703 / 704
页数：2
相关论文
共 9 条
[1]   Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes [J].
Aldridge, KE ;
Ashcraft, DS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) :709-711
[2]  
BEBEAR C, 1985, PATHOL BIOL, V33, P577
[3]   Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones [J].
Bebear, CM ;
Bove, JM ;
Bebear, C ;
Renaudin, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :269-273
[4]   IN-VITRO AND IN-VIVO ACTIVITIES OF SPARFLOXACIN AGAINST MYCOPLASMA-PNEUMONIAE [J].
KAKU, M ;
ISHIDA, K ;
IRIFUNE, K ;
MIZUKANE, R ;
TAKEMURA, H ;
YOSHIDA, R ;
TANAKA, H ;
USUI, T ;
TOMONO, K ;
SUYAMA, N ;
KOGA, H ;
KOHNO, S ;
HARA, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) :738-741
[5]   Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219) [J].
Kenny, GE ;
Cartwright, FD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (04) :1048-1049
[6]   SUSCEPTIBILITIES OF MYCOPLASMA-HOMINIS, MYCOPLASMA-PNEUMONIAE, AND UREAPLASMA-UREALYTICUM TO A NEW QUINOLONE, OPC 17116 [J].
KENNY, GE ;
CARTWRIGHT, FD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (08) :1726-1727
[7]  
Renaudin H, 1995, Drugs, V49 Suppl 2, P243
[8]   INVITRO SUSCEPTIBILITIES OF MYCOPLASMA-PNEUMONIAE, MYCOPLASMA-HOMINIS, AND UREAPLASMA-UREALYTICUM TO SPARFLOXACIN AND PD-127391 [J].
WAITES, KB ;
DUFFY, LB ;
SCHMID, T ;
CRABB, D ;
PATE, MS ;
CASSELL, GH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (06) :1181-1185
[9]   In vitro activity of BAY 12-8039, a new fluoroquinolone [J].
Woodcock, JM ;
Andrews, JM ;
Boswell, FJ ;
Brenwald, NP ;
Wise, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) :101-106
1